Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin‐4‐IgG4‐Fc in healthy subjects: A phase 1, single‐centre, randomized, double‐blind, dose escalation study

Aim Novel long‐acting drugs for type 2 diabetes mellitus may optimize patient compliance and glycaemic control. Exendin‐4‐IgG4‐Fc (E4F4) is a long‐acting glucagon‐like peptide‐1 receptor agonist. This first‐in‐human study investigated the safety, tolerability, pharmacokinetic, pharmacodynamic and im...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2024-04, Vol.26 (4), p.1395-1406
Hauptverfasser:	Chen, Gui‐Ling, Liu, Yang, Gao, Xue‐Feng, Wu, Kai‐Qi, Yang, Yun‐Kai, Chen, Yong, Peng, Cong‐Gao, Jin, Ting‐Han, Huang, Yu‐Bao, Zhang, Yao‐Wen, Su, Jing, Jiang, Qi, Guo, Tong, Zhao, Jie, Peng, Xiang‐Nan, Peng, Jing‐Yu, Li, Si‐Xiu, Sun, Yong‐Li, Zhang, Hong‐Mei, Fu, Yan‐Li, Luo, Dan, Ma, Yaru, Shen, Zhen‐Wei, Zhang, Yun‐Tao, Shou, Zhang‐Fei
Format:	Artikel
Sprache:	eng
Schlagworte:	Area Under Curve Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Dose-Response Relationship, Drug Double-Blind Method E4F4 Exenatide - adverse effects GLP-1 receptor agonists GLP‐1 RA Glucagon Glucose tolerance Glucose Tolerance Test Healthy Volunteers Humans Immunogenicity Immunoglobulin G Pharmacodynamics Pharmacokinetics phase I clinical trial Placebos Safety type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!